JoeY.ChangMDPhD, FASTRO

Summary

• Dr. Chang is a thoracic radiation oncologist with more than 30 years of clinical and research experience. He holds a tenured Texas 4000 Distinguished Professorship and Director of Stereotactic Ablative Radiotherapy (SABR) Program at MD Anderson Cancer Center. Additionally, he is honored as Fellow of American Society of Radiation Oncology (ASTRO) and Fellow of American College of Radiology (ACR). He has also been recognized with the Best Doctors of America award. He is a voting committee member of NCCN thoracic guidelines, Board Director of International Association for the Study of Lung Cancer (IASLC) and Clinical Scientific Program Chair for Particle Therapy Cooperative Group (PTCOGF). He served as chair of both the international proton therapy PTCOG thoracic and American Radium Society Thoracic AUC committees.
  As one of the pioneers in the field of stereotactic ablative radiotherapy (SABR), proton therapy and immunotherapy for lung cancer, he has published more than 330 peer-reviewed articles in prestigious journals, including LANCET, Nature, JAMA, Journal of Clinical Oncology, Journal of Thoracic Oncology, Int J Radiat Oncol Biol Phys (RED J) and various others. His prospective studies including randomized studies comparing surgery vs. SABR in operable stage I lung cancer, stereotactic proton vs. photon radiotherapy in clinical challenging early-stage lung cancer, concurrent proton therapy and chemotherapy in stage III lung cancer, the implementation of intensity-modulated proton therapy (IMPT) in lung cancer, randomized study to compare SABR alone vs. SABR plus immunotherapy (I-SABR) were the first reported clinical studies in the world to do so. His research has helped to establish the role of SABR, proton therapy, and combined immunotherapy and SABR (I-SABR) in early-stage lung cancer.